Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Red-P: BMS-986218 + Degarelix in Prostate Cancer
NCT04301414Phase 1Completed
- Sponsor
- Columbia University
- Start
- Feb 2020
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BMS-986218 in prostate cancer (PCa) (3 arms), sponsored by Columbia University. Primary endpoint: Proportion of patients with an adverse event at 42 months. Started Feb 2020; status: completed.
02
Drugs
BMS-986218
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04301414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301414.